Current Assets
Cash, Cash Equivalents, and Marketable Securities
Guardant Health Cash, Cash Equivalents, and Marketable Securities decreased by 11.1% to $1.12B in Q1 2026 compared to the prior quarter.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ3 2022
Last reportedQ1 2026May 7, 2026
Metric ID:
cash_equivalents_marketable_securities_totalHistorical Data
7 periods
| Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $956.47M | $856.73M | $690.39M | $525.08M | $258.5M | $1.26B | $1.12B |
| QoQ Change | — | -10.4% | -19.4% | -23.9% | -50.8% | +386.5% | -11.1% |
| YoY Change | — | — | — | — | -73.0% | — | — |
Range$258.5M – $1.26B
CAGR+11.0%
Avg YoY Growth-73.0%
Median YoY Growth-73.0%
Cash, Cash Equivalents, and Marketable Securities at Other Companies
Frequently Asked Questions
- What is Guardant Health's cash, cash equivalents, and marketable securities?
- Guardant Health (GH) reported cash, cash equivalents, and marketable securities of $1.12B in Q1 2026.